Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Authors:
- 11 December 2017
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 168 (2) , 389-399
Abstract
PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China’s registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy.Keywords
Funding Information
- Shangdong New Time Pharmaceutical Co., LTD.
This publication has 18 references indexed in Scilit:
- Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?Journal of the National Comprehensive Cancer Network, 2014
- Neutrophils mediate antibody-induced antitumor effects in miceBlood, 2013
- Neutrophil Function: From Mechanisms to DiseaseAnnual Review of Immunology, 2012
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisBMC Cancer, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applicationsAnnals of Oncology, 2010
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Chemotherapy‐induced neutropeniaCancer, 2004
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988